Graybug Vision, INC.: management transactions · United States · SEC (Form 4)

About Graybug Vision, INC.

GRAYBUG VISION, INC. was a United States biopharmaceutical company that traded on the NASDAQ market under the ticker GRAY before its 2023 name change following a merger with CalciMedica. For investors analyzing the company through its legacy identity, Graybug sat squarely in the ophthalmic biotech niche: a high-risk, high-capital-intensity segment focused on retinal and optic nerve diseases. The company was founded in May 2011 on technology licensed from the Johns Hopkins University School of Medicine and operated from facilities in Redwood City, California, and Baltimore, Maryland. Its historical business model centered on research and development, clinical validation, and the creation of long-acting ocular therapies designed to reduce the need for frequent intraocular injections. Graybug’s core pipeline historically included GB-102, a microparticle depot formulation of sunitinib malate aimed at retinal diseases including wet age-related macular degeneration; GB-401, a depot formulation for primary open-angle glaucoma; and GB-103, a longer-acting version of GB-102. The investment case was built around proprietary ocular-delivery technologies intended to maintain therapeutic drug levels in eye tissue for extended periods, with the goal of improving adherence, reducing treatment burden, and potentially lowering the overall burden on the healthcare system. In a competitive landscape dominated by major ophthalmology franchises and a long list of venture-backed biotech peers, Graybug’s positioning was specialized and dependent on successful clinical readouts, regulatory progress, and possible partnering transactions. From a capital-markets perspective, Graybug began trading on the NASDAQ Global Market in September 2020 after its IPO, giving it access to public-market funding and greater visibility among U.S. investors. Recent company milestones were largely strategic rather than commercial: in 2021 and 2022 the company continued to discuss development progress across its retina and glaucoma programs, and in March 2023 it completed a major corporate transformation by changing its name to CalciMedica, Inc. For international investors, the key point is that Graybug Vision is a U.S. biotech story rooted in ophthalmology, with its historical SEC disclosures, legacy Form 4 activity, and pipeline narrative still relevant when reviewing older filings under the Graybug name.